The Ubiquitin/UBL Drug Target Repertoire

Hugh C Osborne; Elsa Irving; Christine K Schmidt

doi:10.1016/j.molmed.2020.08.009

The Ubiquitin/UBL Drug Target Repertoire

Trends Mol Med. 2020 Dec;26(12):1133-1134. doi: 10.1016/j.molmed.2020.08.009. Epub 2020 Sep 24.

Authors

Hugh C Osborne¹, Elsa Irving², Christine K Schmidt³

Affiliations

¹ Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre, Manchester M20 4GJ, UK.
² Bioscience, Oncology R&D, AstraZeneca, Cambridge CB4 0WG, UK.
³ Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Cancer Research Centre, Manchester M20 4GJ, UK. Electronic address: christine.schmidt@manchester.ac.uk.

PMID: 32981839
DOI: 10.1016/j.molmed.2020.08.009

No abstract available

Keywords: deubiquitylating enzyme; heterobifunctional degrader; proteasome inhibitor; ubiquitin and ubiquitin-like protein (UBL); ubiquitin proteasome system.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Drug Development
Humans
Ligands
Molecular Targeted Therapy
Proteasome Endopeptidase Complex / metabolism
Proteasome Inhibitors / pharmacology
Proteolysis
Ubiquitin / antagonists & inhibitors*
Ubiquitin / metabolism*
Ubiquitins / antagonists & inhibitors*
Ubiquitins / metabolism*

Substances

Ligands
Proteasome Inhibitors
Ubiquitin
Ubiquitins
Proteasome Endopeptidase Complex